Cannabix Technologies Provides Technology Update on Marijuana Breathalyzer Development

VANCOUVER, British Columbia, Aug. 27, 2018  -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”) developer of the Cannabix Marijuana Breathalyzer for law enforcement and the workplace, is pleased to report that characterization work has demonstrated the ability to isolate ∆9-tetrahydrocannabinol (“THC”) and suppress background substrates effectively. Cannabix is developing an innovative FAIMS (field asymmetric waveform ion mobility spectrometry) based instrument for the detection of THC. Using the gold standard of mass spectrometry in tandem with the Cannabix FAIMS prototype device, Graph A and B below show suppression of background matrix allowing the THC peak to be easily recognized.  
Published: 30 August 2018
Written by Editor
Project Update   TSXV  
Read more: Cannabix Technologies ( BLO )

Auris Medical Announces Publication Related to AM-111 in Peer-Reviewed Scientific Journal

Zug, Switzerland, May 4, 2018 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, today announced the publication of an article reviewing the mechanism of action, pharmacokinetics and therapeutic applications of AM-111, its investigational treatment for acute inner ear hearing loss. The peer-reviewed article "Preclinical and clinical otoprotective applications of cell-penetrating peptide D-JNKI-1 (AM-111)" was published in Hearing Research, one of the leading journals in the otorhinolaryngology field.  
Published: 04 May 2018
Written by Editor
Nasdaq   Up on News   Project Update  
Read more: Auris Medical Holding AG ( EARS )

Ceapro Inc. Provides Corporate Update

- Company well poised to transition to its next phase of growth for expansion into the profitable nutraceutical sector over the next 12 months -
- Data expected from the bioavailability study of CoQ10-beta glucan and results of the avenanthramides in exercise-induced inflammation in Q2 2018 -
 
EDMONTON, Alberta, April 23, 2018 -- Ceapro Inc.  (TSX-V:CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today provided a summary of 2017 key accomplishments and recent highlights.
 
“We have made significant progress in 2017 on all fronts. Our de-risked business model through the offering of active ingredients to the cosmeceuticals market has once again proven to be fruitful. This base business has enabled us to maintain a solid balance sheet even while initiating the diversification of Ceapro’s business model from a contract manufacturer (CMO) to a biopharmaceutical company that requires significant investment in Research and Development (R&D). Moving forward, we have a clear strategic path.
Published: 24 April 2018
Written by Editor
TSXV  
Read more: Ceapro Inc ( CZO )

Spectrum Pharmaceuticals Announces Update of MD Anderson ’s Phase 2 Data Studying Poziotinib in EGFR Exon 20 Mutant Non-Small Cell Lung Cancer Patients

HENDERSON, Nev. -- Spectrum Pharmaceuticals, Inc ( SPPI ), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that updated poziotinib Phase 2 data in MD Anderson’s EGFR Exon 20 Mutant Non-Small Cell Lung Cancer study are available, based on longer follow-up.
 
“I am pleased to observe the preliminary confirmed objective response rate and potential progression-free survival (PFS) benefit in EGFR Exon 20 Mutant Non-Small Cell Lung Cancer patients,” said John Heymach, M.D., Ph.D., Chairman and Professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center. “In the first 11 patients, the confirmed objective response rate was 64%. 
Published: 10 April 2018
Written by Editor
Nasdaq   Up on News   Project Update  
Read more: Spectrum Pharmaceuticals ( SPPI )

EyeGate Completes Enrollment and Receives Milestone Payment for Confirmatory Phase 3 Clinical Study of EGP-437 in Anterior Uveitis

WALTHAM, Mass., April 06, 2018  -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), today announced completion of patient enrollment for the pivotal Phase 3 clinical study of its EGP-437 combination product for the treatment of non-infectious anterior uveitis.
 
Non-infectious anterior uveitis is characterized by the inflammation of the anterior chamber of the eye. Symptoms may include redness, soreness and inflammation of the eye, blurring of vision, sensitivity to light and a small pupil. If untreated anterior uveitis can cause permanent damage and vision loss.
Published: 06 April 2018
Written by Editor
Nasdaq   Up on News   Project Update  
Read more: EyeGate Pharmaceuticals ( EYEG )
  1. Heron Therapeutics ( HRTX )
  2. Daxor Corporation ( DXR )
  3. Arcadia Biosciences ( RKDA )
  4. Vericel Corporation ( VCEL )
  5. Clearside Biomedical ( CLSD )

Videos / Webinars

View all videos